PT1043025E - Tratamento de carcinoma da celula renal - Google Patents

Tratamento de carcinoma da celula renal

Info

Publication number
PT1043025E
PT1043025E PT00107100T PT00107100T PT1043025E PT 1043025 E PT1043025 E PT 1043025E PT 00107100 T PT00107100 T PT 00107100T PT 00107100 T PT00107100 T PT 00107100T PT 1043025 E PT1043025 E PT 1043025E
Authority
PT
Portugal
Prior art keywords
carcinoma
treatment
renal cell
renal
cell
Prior art date
Application number
PT00107100T
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PT1043025E publication Critical patent/PT1043025E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT00107100T 1999-04-08 2000-04-06 Tratamento de carcinoma da celula renal PT1043025E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
PT1043025E true PT1043025E (pt) 2005-09-30

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
PT05002952T PT1535623E (pt) 1999-04-08 2000-04-06 Tratamento para carcinoma de células renais
PT00107100T PT1043025E (pt) 1999-04-08 2000-04-06 Tratamento de carcinoma da celula renal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT05002952T PT1535623E (pt) 1999-04-08 2000-04-06 Tratamento para carcinoma de células renais

Country Status (24)

Country Link
EP (2) EP1043025B1 (pt)
JP (2) JP3712914B2 (pt)
CN (1) CN1367702A (pt)
AR (1) AR029160A1 (pt)
AT (2) ATE419002T1 (pt)
AU (2) AU777406B2 (pt)
BR (1) BR0009644A (pt)
CA (1) CA2303752A1 (pt)
CO (1) CO5170412A1 (pt)
CY (1) CY1108919T1 (pt)
DE (2) DE60041291D1 (pt)
DK (2) DK1043025T3 (pt)
ES (2) ES2239953T3 (pt)
HK (2) HK1032533A1 (pt)
HU (1) HU230271B1 (pt)
MX (1) MXPA00003401A (pt)
MY (1) MY155221A (pt)
NO (1) NO328983B1 (pt)
NZ (1) NZ514629A (pt)
PE (1) PE20010026A1 (pt)
PT (2) PT1535623E (pt)
TW (2) TW200526243A (pt)
WO (1) WO2000061174A2 (pt)
ZA (1) ZA200108169B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061174A2 (en) * 1999-04-08 2000-10-19 Schering Corporation Use of pegylated interferon alpha for renal cell carcinoma treatment
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
EP2552443B1 (en) 2010-04-01 2021-07-14 Oncorena Ab Improved treatment of renal cell carcinoma
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
KR100420642B1 (ko) * 1998-03-26 2004-03-02 쉐링 코포레이션 Peg-인터페론 알파 결합체의 보호에 사용되는 제형
WO2000061174A2 (en) * 1999-04-08 2000-10-19 Schering Corporation Use of pegylated interferon alpha for renal cell carcinoma treatment

Also Published As

Publication number Publication date
HUP0200781A2 (en) 2002-08-28
NO20014851D0 (no) 2001-10-05
MXPA00003401A (es) 2002-03-08
WO2000061174A2 (en) 2000-10-19
AU2004242454A1 (en) 2005-01-20
HK1075417A1 (en) 2005-12-16
CO5170412A1 (es) 2002-06-27
PT1535623E (pt) 2009-03-19
DK1535623T3 (da) 2009-04-27
DE60020442D1 (de) 2005-07-07
HK1032533A1 (en) 2001-07-27
ATE296638T1 (de) 2005-06-15
PE20010026A1 (es) 2001-02-05
EP1535623A1 (en) 2005-06-01
AU2004242454B2 (en) 2007-02-15
ATE419002T1 (de) 2009-01-15
CY1108919T1 (el) 2014-07-02
ES2319777T3 (es) 2009-05-12
JP4721488B2 (ja) 2011-07-13
EP1043025A3 (en) 2000-12-20
ES2239953T3 (es) 2005-10-16
AU777406B2 (en) 2004-10-14
WO2000061174A3 (en) 2001-01-25
TW200526243A (en) 2005-08-16
NZ514629A (en) 2004-02-27
DE60041291D1 (de) 2009-02-12
CA2303752A1 (en) 2000-10-08
AU4204400A (en) 2000-11-14
HU230271B1 (hu) 2015-11-30
JP2001288110A (ja) 2001-10-16
EP1535623B1 (en) 2008-12-31
CN1367702A (zh) 2002-09-04
ZA200108169B (en) 2003-01-06
EP1043025B1 (en) 2005-06-01
TWI310314B (en) 2009-06-01
BR0009644A (pt) 2002-01-08
AR029160A1 (es) 2003-06-18
DK1043025T3 (da) 2005-07-04
EP1043025A2 (en) 2000-10-11
HUP0200781A3 (en) 2002-09-30
DE60020442T2 (de) 2006-05-04
NO20014851L (no) 2001-12-07
MY155221A (en) 2015-09-30
JP3712914B2 (ja) 2005-11-02
NO328983B1 (no) 2010-07-05
JP2000319196A (ja) 2000-11-21

Similar Documents

Publication Publication Date Title
DE69933078D1 (de) Stent Aneurismus-Behandlungssystem
DE60001530D1 (de) Verbinder
DE60006630D1 (de) Verbinder
DE10084903T1 (de) Polyetherpolyurethan
DE60020922D1 (de) Verbinder
DE60027115D1 (de) Wasserbehandlungssystem
DE60044131D1 (de) Katheter
FI20000863A (fi) Uusi hoitomenetelmä
DE60042231D1 (de) Verbinder
DE69920862D1 (de) Verbinder
DE60026459D1 (de) Simethicon enthaltendes Abführmittel
DE60008069D1 (de) Verbinder
DE60001032T2 (de) Verbinder
DE60019059D1 (de) Verbinder
DE60027329D1 (de) Biokompatible katheter
DE60037233D1 (de) Hämofiltrationsvorrichtung
DE60043606D1 (de) Verbinder
DE60025681D1 (de) Verbinder
DE60015473D1 (de) Verbinder
DE60027520D1 (de) Verbinder
DE60026234D1 (de) Verbinder
DE60001783D1 (de) Verbinder
DE60003993D1 (de) Verbinder
HK1075417A1 (en) Renal cell carcinoma treatment
NO20013596L (no) Slambehandling